Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia (SMARTER)

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Asthma

Treatments: Drug: Symbicort Turbuhaler 160/4.5

Study type: Interventional

Funder types: Industry

Identifiers

NCT00576316

D5890L00027

Details and patient eligibility

About

The purpose of the study is to evaluate the satisfaction level of patients using the Symbicort SMART approach for their asthma management.

Enrollment: 201 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of asthma for past 6 months and treated with inhaled glucocorticosteroids for at least 3 months.
• Patients who asthma is classified as uncontrolled or partially controlled as defined by GINA 2006 guidelines.

Exclusion criteria

• Patients already on Symbicort SMART treatment.
• Patients who has respiratory tract infection 30 days before study enrolment.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)